Wave Life Sciences Ltd. (WVE)

Market Cap	2.74B
Revenue (ttm)	109.23M
Net Income (ttm)	-121.95M
Shares Out	167.18M
EPS (ttm)	-0.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,102,004
Open	16.80
Previous Close	16.11
Day's Range	16.14 - 17.41
52-Week Range	5.28 - 21.73
Beta	-1.72
Analysts	Strong Buy
Price Target	29.44 (+79.4%)
Earnings Date	Nov 10, 2025

About WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 288
• Stock Exchange: NASDAQ
• Ticker Symbol: WVE
• Website: https://wavelifesciences.com

Financial Performance

In 2024, Wave Life Sciences's revenue was $108.30 million, a decrease of -4.42% compared to the previous year's $113.31 million. Losses were -$97.01 million, 68.7% more than in 2023.

Analyst Summary

According to 16 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $29.44, which is an increase of 79.40% from the latest price.

Price Target

$29.44

(79.40% upside)

Analyst Consensus: Strong Buy